At a Recent Cancer Research Conference, Instil Bio Stole the Show
At the mid-April American Association of Cancer Research Annual Meeting, bleeding-edge oncology company Instil Bio (NASDAQ:TIL) reported promising results for one of its candidate therapies. In a compassionate-use program, the company's tumor-infiltrating lymphocyte (TIL) therapy had an impressive overall response rate in an especially difficult-to-treat stage IV metastatic melanoma population. The $2.1 billion market cap biotech expects to begin a phase 2 trial of the treatment in the second half of 2021, with data to be delivered in 2023. Here's what biotech investors need to know from th...